KDM1A and small cell lung carcinoma: In this context, cfDNA methylomics may be a valuable technology for understanding kinetics of SCLC heterogeneity and personalizing treatment for patients [48], potentially through the use of EZH2 or LSD1 inhibition [25, 33].